Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medigene ( (DE:MDG1) ) just unveiled an update.
Medigene AG’s insolvency administrator has moved to revoke the admission of the company’s shares to trading on the regulated market in Frankfurt, citing legal provisions under the German Stock Exchange Act. The decision follows the complete suspension of Medigene’s operational business shortly after insolvency proceedings began and its ongoing liquidation, with the delisting aimed at protecting market participants and ensuring the integrity of stock exchange trading.
With no remaining operating activities, Medigene is effectively being wound down, and continued listing of its shares is deemed incompatible with orderly market conditions. The planned revocation marks a further step in the company’s dismantling process and underscores the risks for shareholders in insolvent issuers whose securities can no longer be traded reliably over the long term.
More about Medigene
Medigene AG is a Germany-based biotechnology company that had focused on developing innovative therapies in the life sciences sector. The company’s shares have been listed on the regulated market in Frankfurt and on several German free markets, giving investors access to its stock across multiple trading venues.
Average Trading Volume: 4,624
Technical Sentiment Signal: Sell
Current Market Cap: €556.8K
Find detailed analytics on MDG1 stock on TipRanks’ Stock Analysis page.